Go or no go? Apellis eyes an FDA outcome
Immunogen and Uniqure are also set for Pdufa conclusions.
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.